MSI‐H/mutBRAF tumors develop in the serrated pathway and belong to the consensus molecular subtype 1 classification of CRC, associated with poor survival after relapse.33 In the two immunotherapy trials including patients with mutBRAF tumors, the response rate and survival did not significantly differ according to BRAF status, but the numbers were limited. The gene discussed is BRAF; the disease is colorectal carcinoma.